Evangeline Chee
•Download as PPTX, PDF•
0 likes•267 views
China and India are now able to copy complex biotech drugs used to treat cancer and other diseases, bypassing patents held by pharmaceutical companies in richer countries. This allows cheaper generic versions of drugs to be sold in developing countries, reducing healthcare costs but threatening the profits of brand-name drug makers. However, pharmaceutical firms and their allies in wealthier nations are fighting back against this circumvention of patents, creating a dilemma that mirrors the debate around access to AIDS drugs a decade ago over who should have the right to produce lower-cost versions of life-saving medicines.
Report
Share
Report
Share
Recommended
Building Biotechnology in India
This document discusses global perspectives on industrial biotechnology. It begins by looking at how location affects biotechnology development and compares technology producers to consumers. It then examines why the U.S. is a global leader in biotechnology and discusses the developing country perspective using the Philippines as a case study. The document also addresses acquiring medicines, producing drugs locally, and the costs of weak patent protection. It concludes by looking at different models for meeting national needs through economic development.
How to Communicate Effectively
2º Class of the 2010 Course of Business Communication of the Economics School at Navarra University
Entrepreneurial Scotland
Companies all over the world come to Regus to find the flexible workspace that enables them to do business more effectively. We have over 800,000 customers using our business centres every day, this gives us a wealth of experience in all workplace issues. If you’re looking for an expert to speak at your event, big or small, we are happy to provide trained speakers to talk about the issues your audience want to discuss.
Please contact Henry Collinge at press.office@regus.com if you would like a Regus speaker to present at your event.
Find out more about Regus: http://www.regus.com/?utm_campaign=slideshare
Pharmaceutical globalization: Where are drugs invented?
The document discusses the globalization of drug discovery and development. It examines factors that influence where research and production occurs such as workforce costs, market size, intellectual property laws, and government policies. Countries like the US and Europe have traditionally led in innovation due to strong markets and patent protection, but Asia is increasing its role with lower costs and a growing skilled workforce. Where drugs are invented is shifting over time, with the US share declining and Asia rising in recent decades.
Evangeline Chee - China and India making inroads in Biotech Drugs
1) Chinese and Indian drug makers are on the verge of selling cheaper copies of complex biotech drugs to treat diseases like cancer, diabetes, and arthritis that are currently only affordable in rich nations.
2) This could transform healthcare in much of the world but spark backlash from major pharmaceutical companies and rich countries seeking to protect drug patents.
3) Advocates argue these copycat drugs could increase access to life-saving treatments, while others argue ensuring drug company profits is needed to drive innovation.
biotech
The document recommends an overweight position in the healthcare biotechnology industry. Major companies are seeing double digit revenue growth and high profit margins due to limited competition from patents. However, government regulation poses a threat if it imposes price caps or reduces patent lives. Additionally, companies rely on a small number of "star drugs" whose expiration or replacement could significantly harm their value.
Using patent information to track globalization
This document discusses using patent information to track the globalization of innovation in the biopharmaceutical industry. It examines how location affects R&D and production decisions and outlines three models countries use: weak intellectual property laws to focus on generic production (India, Brazil, Thailand), moderate intellectual property to leverage generic skills and develop innovative drugs (Israel, Cuba), and strong intellectual property to attract manufacturing investments (Singapore, Puerto Rico). Analysis of patent data shows while the US remains the top location for pharmaceutical innovation, Asia is rising and the EU is stable as the US is slipping as the sole global leader.
Eli Lilly Global Strategy
- The document analyzes the five forces model, PESTLE analysis, and SWOT analysis for a pharmaceutical company.
- It identifies strong competition from generic drugs, high R&D costs, and stringent FDA regulations as challenges.
- Opportunities include the aging population, globalization, and emerging markets in developing countries.
Recommended
Building Biotechnology in India
This document discusses global perspectives on industrial biotechnology. It begins by looking at how location affects biotechnology development and compares technology producers to consumers. It then examines why the U.S. is a global leader in biotechnology and discusses the developing country perspective using the Philippines as a case study. The document also addresses acquiring medicines, producing drugs locally, and the costs of weak patent protection. It concludes by looking at different models for meeting national needs through economic development.
How to Communicate Effectively
2º Class of the 2010 Course of Business Communication of the Economics School at Navarra University
Entrepreneurial Scotland
Companies all over the world come to Regus to find the flexible workspace that enables them to do business more effectively. We have over 800,000 customers using our business centres every day, this gives us a wealth of experience in all workplace issues. If you’re looking for an expert to speak at your event, big or small, we are happy to provide trained speakers to talk about the issues your audience want to discuss.
Please contact Henry Collinge at press.office@regus.com if you would like a Regus speaker to present at your event.
Find out more about Regus: http://www.regus.com/?utm_campaign=slideshare
Pharmaceutical globalization: Where are drugs invented?
The document discusses the globalization of drug discovery and development. It examines factors that influence where research and production occurs such as workforce costs, market size, intellectual property laws, and government policies. Countries like the US and Europe have traditionally led in innovation due to strong markets and patent protection, but Asia is increasing its role with lower costs and a growing skilled workforce. Where drugs are invented is shifting over time, with the US share declining and Asia rising in recent decades.
Evangeline Chee - China and India making inroads in Biotech Drugs
1) Chinese and Indian drug makers are on the verge of selling cheaper copies of complex biotech drugs to treat diseases like cancer, diabetes, and arthritis that are currently only affordable in rich nations.
2) This could transform healthcare in much of the world but spark backlash from major pharmaceutical companies and rich countries seeking to protect drug patents.
3) Advocates argue these copycat drugs could increase access to life-saving treatments, while others argue ensuring drug company profits is needed to drive innovation.
biotech
The document recommends an overweight position in the healthcare biotechnology industry. Major companies are seeing double digit revenue growth and high profit margins due to limited competition from patents. However, government regulation poses a threat if it imposes price caps or reduces patent lives. Additionally, companies rely on a small number of "star drugs" whose expiration or replacement could significantly harm their value.
Using patent information to track globalization
This document discusses using patent information to track the globalization of innovation in the biopharmaceutical industry. It examines how location affects R&D and production decisions and outlines three models countries use: weak intellectual property laws to focus on generic production (India, Brazil, Thailand), moderate intellectual property to leverage generic skills and develop innovative drugs (Israel, Cuba), and strong intellectual property to attract manufacturing investments (Singapore, Puerto Rico). Analysis of patent data shows while the US remains the top location for pharmaceutical innovation, Asia is rising and the EU is stable as the US is slipping as the sole global leader.
Eli Lilly Global Strategy
- The document analyzes the five forces model, PESTLE analysis, and SWOT analysis for a pharmaceutical company.
- It identifies strong competition from generic drugs, high R&D costs, and stringent FDA regulations as challenges.
- Opportunities include the aging population, globalization, and emerging markets in developing countries.
Genentech
A presentation of Genentech strategic growth options vis-a-vis the current economic and structural challenges the biotech industry is facing.
Team project, December 2008.
Changing the Medical Research Paradigm
Presentation on current state of pharmaceutical drug research and ideas for change. It addresses how the pharmaceutical industry, NIH, Government, HealthCare Law, OIG, Public Health
Pharmaceutical%20 industry%20final
The pharmaceutical industry has grown significantly since the Middle Ages. Major players in the industry invest heavily in research and development to create new drugs, though this process is long and expensive. The industry employs just-in-time manufacturing techniques to reduce waste. Large companies focus on research while smaller companies specialize in manufacturing. The U.S. market offers less growth potential than international markets in developing countries. The industry faces challenges such as intense competition, varying regulations between countries, and ensuring drugs meet sales goals before patents expire.
Health profits before people
The document discusses intellectual property rights (IPR) and the pharmaceutical industry. It notes that while IPR are meant to foster innovation, they can also limit access to medicines and raise prices. The document examines issues around IPR, pricing, access to medicines, and incentives for research and development. It provides background on epidemics like polio, malaria, and cholera. The document analyzes how IPR impact the pharmaceutical industry, including in India, and notes challenges in balancing IPR with public health concerns.
Groelle_GlobalRegulatoryConsiderationsBiosimilars_13Jun14
This document summarizes global regulatory considerations for biosimilars. It discusses the 12-year exclusivity period for reference biologics in the US according to the Biologics Price Competition and Innovation Act, as well as the 10-year exclusivity period plus potential 1-year extension in Europe. Regulations vary by country and region, with some like China and India having established guidance and many biosimilar trials, while others like Russia and Latin American countries are still developing related legislation. The document provides an overview of exclusivity periods and approval pathways for biosimilars in major regions worldwide.
Presentation
The document discusses the Indian pharmaceutical industry and the market for generic drugs. It provides background on key policies that promoted the growth of the Indian generic drug industry, including the Patent Act of 1970. It outlines the strengths and weaknesses of the Indian pharmaceutical industry. It also discusses the significant role of the Indian pharmaceutical industry in supplying generic drugs globally, particularly to regulated markets like the US. The industry is expected to continue growing and shifting to focus more on R&D and manufacturing of value-added drugs.
Indian pharma and generic medicines
In any country, research and studies pertaining to medicines tend to be expensive. That is why companies researching new medicines tend to pass on these costs to consumers. However, a look at profits raked in by drug companies indicates that pharmaceutical (pharma) companies do tend to overprice medicines. Given that quality healthcare is essential for all, the society at large suffers due to the extravagant prices of good medication. This is where generic medicines come in.
Drug Patency
The document discusses various aspects of drug patents including definitions, requirements, strategies, advantages and disadvantages. It defines a patent as a property right granted to an inventor that allows them to exclude others from making or selling their invention for a limited time in exchange for publicly disclosing the invention. Key requirements for a patent include novelty, inventive step, industrial applicability and sufficiency of disclosure. The document also discusses the role of patents in incentivizing drug development and issues around access to medicines, including evergreening and TRIPS waivers.
patency-180312090413 (1).pptx
The document discusses various aspects of drug patents including definitions, requirements, processes, strategies, impacts and issues. Some key points:
- A patent grants an inventor exclusive rights to an invention for a limited time (usually 20 years) in exchange for publicly disclosing the invention. It does not permit marketing the product which requires separate regulatory approval.
- To be patentable, an invention must be novel, involve an inventive step, and be industrially applicable. Strategies to extend patents include new formulations, uses and combinations.
- The TRIPS agreement harmonized intellectual property standards globally but some argue this restricts access to medicines in developing countries. The WTO recently approved a waiver allowing least developed countries
Ethical Implications of Orphan Drug Research Incentives
1. This presentation will go over the implications of research incentives limited to orphan drugs.
2. It will demonstrate the case and summarize the key points from a high level. Furthermore, this will provide a basis on how to address the the dilemmas.
NOTE - This presentation was made as part of an assignment for a Course PME 542 (Regulation and Compliance in the Pharmaceutical Industry) at Stevens Institute of Technology, Hoboken, New Jersey
Prepared By - Jing Mi, Ali Raza and Kuldeep Badoniya
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Global Study Solutions - 9901366442
Managers in the pharmaceutical industry face both opportunities and threats due to a dynamic environment. Demand for pharmaceuticals has grown steadily for decades due to demographics and successful new drugs can be highly profitable. However, developing new drugs takes 10-15 years and costs $800 million on average, with many failing. Additionally, incumbent firms face challenges such as upcoming patent expirations, potential price controls, and reduced prices negotiated by large health providers.Healthcare Industry Analysis for Investors
The document discusses the healthcare sector as an investment opportunity. It notes that healthcare demand is defensive as people will still need it even during economic downturns. It identifies top industry players as drug companies, biotech companies, and medical device companies. Drug companies and device firms tend to have strong competitive advantages or "wide economic moats" due to high costs of research and development, patent protection, and other barriers to entry. However, the sector also carries risks such as long development timelines for drugs, regulatory hurdles, and loss of revenue when patents expire. The document provides an overview of factors to consider when evaluating investment opportunities in healthcare companies.
pharmaceutical-industry-r-d-an-inside-out-look.ppt
The pharmaceutical industry is facing many challenges in research and development including increased costs, higher hurdles for drug approval, and loss of blockbuster drugs to generics. As a result, the traditional model of large pharmaceutical companies conducting all research and development in-house has changed. The industry now involves a complex network of large companies, startups, contract research organizations, academic labs, and other partners. Opportunities still exist for students in the sciences but lie in more specialized areas such as clinical operations, business development, and roles outside of traditional drug discovery that apply scientific skills and knowledge. Emerging areas of focus include biotechnology, biomarkers, cancer immunotherapy, and bioelectronics.
Crystina Riffel: Pharmaceutical Drug Policies
The document discusses how intellectual property rights and patents create health inequalities between developed and developing countries. It analyzes how the TRIPS agreement established global intellectual property standards but did not consider the needs of poor countries. This allows pharmaceutical companies to charge high prices for drugs in developing countries without generic competition. The document also discusses how South Africa implemented compulsory licensing to access affordable medicines, facing a lawsuit from drug companies, but eventually was able to enforce its law. It proposes alternatives like orphan drug policies and bulk purchasing initiatives to incentivize research for diseases prevalent in developing countries.
Lisman New Paradigms
The document discusses the gap between the regulatory world and medical practice regarding knowledge about approved medications. It notes regulatory authorities have extensive data on medications from clinical trials and pharmacovigilance that could benefit medical practice, but this information is not fully shared due to data protection concerns. The document proposes increased communication and finding common interests to reconcile regulatory and medical perspectives in a new paradigm that optimizes use of knowledge to improve patient care and public health outcomes.
The new war on pharmaceutical drugs
The document discusses the pharmaceutical industry and challenges it faces. It notes that global spending on prescription drugs was $954 billion in 2011 and the top 12 companies by revenue. It also discusses the high costs of research and development, limited intellectual property protection, pressure from generic brands, neglected therapeutic areas, and efforts by PhRMA and governments to improve access to medicines globally.
Feisee Global Ip Challenges Washington Campus 2010
The document summarizes key topics in intellectual property rights and regulations for the biotechnology industry in a global economy, including:
1) The role of patents in promoting innovation in biotechnology by protecting investments in research and development.
2) Challenges around patent reform legislation, healthcare reform provisions for biosimilars, management of intellectual property from federally funded research, and international intellectual property regulations.
3) Opportunities to streamline patent processes, support collaborations, and increase funding for university research to promote continued innovation.
Direct to Consumer Advertising Slides.pdf
This document summarizes information about direct-to-consumer advertising of pharmaceutical products. It notes that the U.S. and New Zealand are the only countries that allow pharmaceutical advertising directly to patients that includes product claims. While some advantages of direct-to-consumer advertising are that it can inform and empower patients, the disadvantages include that it may misinform patients about risks and benefits, encourage overutilization of drugs, and strain relationships with healthcare providers.
Indian Patent Regime after 1995 amendments, NIB patent wars
Post'1995 Indian patent regime, Loopholes, Advantages, disadvantages, Criticality of sec-3(d), NIB patent war and litigations of foreign nnovator companies, Imatinib, sorafenib, etc...
Pharmaceuticals and HIV/AIDS
This presentation quickly presents the current dilemma with generic drugs for HIV/AIDS and 4 proposed solutions to the "patent problem."
Siti Zulaiha Bte Kamarudin (Article)
Herbert Simon argues that our task is not to predict the future, but to shape it. He outlines three conditions for an acceptable future: 1) living sustainably within Earth's limits, 2) fair sharing of resources, and 3) reducing divisions between groups. Technology provides both opportunities and risks, and it is up to us to guide technology's development and use to foster beneficial outcomes for humanity. Computers in particular can help us understand human cognition and design a sustainable future by modeling minds and societies.
Siti Zulaiha Bte Kamarudin
The document discusses shaping the future rather than just predicting it. It argues that our task is to design a sustainable and acceptable future world characterized by living in peace with nature, sharing resources broadly and fairly, and eliminating divisions between groups. The key points are that achieving a sustainable future depends more on addressing people's basic desires than technology alone, and that through present efforts we can determine how sustainable the future will be by focusing on shaping the future rather than just forecasting it.
More Related Content
Similar to Evangeline Chee
Genentech
A presentation of Genentech strategic growth options vis-a-vis the current economic and structural challenges the biotech industry is facing.
Team project, December 2008.
Changing the Medical Research Paradigm
Presentation on current state of pharmaceutical drug research and ideas for change. It addresses how the pharmaceutical industry, NIH, Government, HealthCare Law, OIG, Public Health
Pharmaceutical%20 industry%20final
The pharmaceutical industry has grown significantly since the Middle Ages. Major players in the industry invest heavily in research and development to create new drugs, though this process is long and expensive. The industry employs just-in-time manufacturing techniques to reduce waste. Large companies focus on research while smaller companies specialize in manufacturing. The U.S. market offers less growth potential than international markets in developing countries. The industry faces challenges such as intense competition, varying regulations between countries, and ensuring drugs meet sales goals before patents expire.
Health profits before people
The document discusses intellectual property rights (IPR) and the pharmaceutical industry. It notes that while IPR are meant to foster innovation, they can also limit access to medicines and raise prices. The document examines issues around IPR, pricing, access to medicines, and incentives for research and development. It provides background on epidemics like polio, malaria, and cholera. The document analyzes how IPR impact the pharmaceutical industry, including in India, and notes challenges in balancing IPR with public health concerns.
Groelle_GlobalRegulatoryConsiderationsBiosimilars_13Jun14
This document summarizes global regulatory considerations for biosimilars. It discusses the 12-year exclusivity period for reference biologics in the US according to the Biologics Price Competition and Innovation Act, as well as the 10-year exclusivity period plus potential 1-year extension in Europe. Regulations vary by country and region, with some like China and India having established guidance and many biosimilar trials, while others like Russia and Latin American countries are still developing related legislation. The document provides an overview of exclusivity periods and approval pathways for biosimilars in major regions worldwide.
Presentation
The document discusses the Indian pharmaceutical industry and the market for generic drugs. It provides background on key policies that promoted the growth of the Indian generic drug industry, including the Patent Act of 1970. It outlines the strengths and weaknesses of the Indian pharmaceutical industry. It also discusses the significant role of the Indian pharmaceutical industry in supplying generic drugs globally, particularly to regulated markets like the US. The industry is expected to continue growing and shifting to focus more on R&D and manufacturing of value-added drugs.
Indian pharma and generic medicines
In any country, research and studies pertaining to medicines tend to be expensive. That is why companies researching new medicines tend to pass on these costs to consumers. However, a look at profits raked in by drug companies indicates that pharmaceutical (pharma) companies do tend to overprice medicines. Given that quality healthcare is essential for all, the society at large suffers due to the extravagant prices of good medication. This is where generic medicines come in.
Drug Patency
The document discusses various aspects of drug patents including definitions, requirements, strategies, advantages and disadvantages. It defines a patent as a property right granted to an inventor that allows them to exclude others from making or selling their invention for a limited time in exchange for publicly disclosing the invention. Key requirements for a patent include novelty, inventive step, industrial applicability and sufficiency of disclosure. The document also discusses the role of patents in incentivizing drug development and issues around access to medicines, including evergreening and TRIPS waivers.
patency-180312090413 (1).pptx
The document discusses various aspects of drug patents including definitions, requirements, processes, strategies, impacts and issues. Some key points:
- A patent grants an inventor exclusive rights to an invention for a limited time (usually 20 years) in exchange for publicly disclosing the invention. It does not permit marketing the product which requires separate regulatory approval.
- To be patentable, an invention must be novel, involve an inventive step, and be industrially applicable. Strategies to extend patents include new formulations, uses and combinations.
- The TRIPS agreement harmonized intellectual property standards globally but some argue this restricts access to medicines in developing countries. The WTO recently approved a waiver allowing least developed countries
Ethical Implications of Orphan Drug Research Incentives
1. This presentation will go over the implications of research incentives limited to orphan drugs.
2. It will demonstrate the case and summarize the key points from a high level. Furthermore, this will provide a basis on how to address the the dilemmas.
NOTE - This presentation was made as part of an assignment for a Course PME 542 (Regulation and Compliance in the Pharmaceutical Industry) at Stevens Institute of Technology, Hoboken, New Jersey
Prepared By - Jing Mi, Ali Raza and Kuldeep Badoniya
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Global Study Solutions - 9901366442
Managers in the pharmaceutical industry face both opportunities and threats due to a dynamic environment. Demand for pharmaceuticals has grown steadily for decades due to demographics and successful new drugs can be highly profitable. However, developing new drugs takes 10-15 years and costs $800 million on average, with many failing. Additionally, incumbent firms face challenges such as upcoming patent expirations, potential price controls, and reduced prices negotiated by large health providers.Healthcare Industry Analysis for Investors
The document discusses the healthcare sector as an investment opportunity. It notes that healthcare demand is defensive as people will still need it even during economic downturns. It identifies top industry players as drug companies, biotech companies, and medical device companies. Drug companies and device firms tend to have strong competitive advantages or "wide economic moats" due to high costs of research and development, patent protection, and other barriers to entry. However, the sector also carries risks such as long development timelines for drugs, regulatory hurdles, and loss of revenue when patents expire. The document provides an overview of factors to consider when evaluating investment opportunities in healthcare companies.
pharmaceutical-industry-r-d-an-inside-out-look.ppt
The pharmaceutical industry is facing many challenges in research and development including increased costs, higher hurdles for drug approval, and loss of blockbuster drugs to generics. As a result, the traditional model of large pharmaceutical companies conducting all research and development in-house has changed. The industry now involves a complex network of large companies, startups, contract research organizations, academic labs, and other partners. Opportunities still exist for students in the sciences but lie in more specialized areas such as clinical operations, business development, and roles outside of traditional drug discovery that apply scientific skills and knowledge. Emerging areas of focus include biotechnology, biomarkers, cancer immunotherapy, and bioelectronics.
Crystina Riffel: Pharmaceutical Drug Policies
The document discusses how intellectual property rights and patents create health inequalities between developed and developing countries. It analyzes how the TRIPS agreement established global intellectual property standards but did not consider the needs of poor countries. This allows pharmaceutical companies to charge high prices for drugs in developing countries without generic competition. The document also discusses how South Africa implemented compulsory licensing to access affordable medicines, facing a lawsuit from drug companies, but eventually was able to enforce its law. It proposes alternatives like orphan drug policies and bulk purchasing initiatives to incentivize research for diseases prevalent in developing countries.
Lisman New Paradigms
The document discusses the gap between the regulatory world and medical practice regarding knowledge about approved medications. It notes regulatory authorities have extensive data on medications from clinical trials and pharmacovigilance that could benefit medical practice, but this information is not fully shared due to data protection concerns. The document proposes increased communication and finding common interests to reconcile regulatory and medical perspectives in a new paradigm that optimizes use of knowledge to improve patient care and public health outcomes.
The new war on pharmaceutical drugs
The document discusses the pharmaceutical industry and challenges it faces. It notes that global spending on prescription drugs was $954 billion in 2011 and the top 12 companies by revenue. It also discusses the high costs of research and development, limited intellectual property protection, pressure from generic brands, neglected therapeutic areas, and efforts by PhRMA and governments to improve access to medicines globally.
Feisee Global Ip Challenges Washington Campus 2010
The document summarizes key topics in intellectual property rights and regulations for the biotechnology industry in a global economy, including:
1) The role of patents in promoting innovation in biotechnology by protecting investments in research and development.
2) Challenges around patent reform legislation, healthcare reform provisions for biosimilars, management of intellectual property from federally funded research, and international intellectual property regulations.
3) Opportunities to streamline patent processes, support collaborations, and increase funding for university research to promote continued innovation.
Direct to Consumer Advertising Slides.pdf
This document summarizes information about direct-to-consumer advertising of pharmaceutical products. It notes that the U.S. and New Zealand are the only countries that allow pharmaceutical advertising directly to patients that includes product claims. While some advantages of direct-to-consumer advertising are that it can inform and empower patients, the disadvantages include that it may misinform patients about risks and benefits, encourage overutilization of drugs, and strain relationships with healthcare providers.
Indian Patent Regime after 1995 amendments, NIB patent wars
Post'1995 Indian patent regime, Loopholes, Advantages, disadvantages, Criticality of sec-3(d), NIB patent war and litigations of foreign nnovator companies, Imatinib, sorafenib, etc...
Pharmaceuticals and HIV/AIDS
This presentation quickly presents the current dilemma with generic drugs for HIV/AIDS and 4 proposed solutions to the "patent problem."
Similar to Evangeline Chee (20)
Groelle_GlobalRegulatoryConsiderationsBiosimilars_13Jun14
Groelle_GlobalRegulatoryConsiderationsBiosimilars_13Jun14
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research Incentives
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...
pharmaceutical-industry-r-d-an-inside-out-look.ppt
pharmaceutical-industry-r-d-an-inside-out-look.ppt
Feisee Global Ip Challenges Washington Campus 2010
Feisee Global Ip Challenges Washington Campus 2010
Indian Patent Regime after 1995 amendments, NIB patent wars
Indian Patent Regime after 1995 amendments, NIB patent wars
More from cynrx
Siti Zulaiha Bte Kamarudin (Article)
Herbert Simon argues that our task is not to predict the future, but to shape it. He outlines three conditions for an acceptable future: 1) living sustainably within Earth's limits, 2) fair sharing of resources, and 3) reducing divisions between groups. Technology provides both opportunities and risks, and it is up to us to guide technology's development and use to foster beneficial outcomes for humanity. Computers in particular can help us understand human cognition and design a sustainable future by modeling minds and societies.
Siti Zulaiha Bte Kamarudin
The document discusses shaping the future rather than just predicting it. It argues that our task is to design a sustainable and acceptable future world characterized by living in peace with nature, sharing resources broadly and fairly, and eliminating divisions between groups. The key points are that achieving a sustainable future depends more on addressing people's basic desires than technology alone, and that through present efforts we can determine how sustainable the future will be by focusing on shaping the future rather than just forecasting it.
Luo Jia (Article)
This article examines the relationship between salesperson usage of CRM technology and sales performance. The authors test the assumption that more CRM usage leads to better performance by developing a Technology Performance Model. They analyze data from 131 salespeople and find a curvilinear relationship, where CRM initially enhances performance up to a point, but beyond that point further usage diminishes and can disable performance. This offers valuable insight for practitioners on achieving optimal technology usage levels to maximize sales performance.
Luo Jia
This document discusses how customer relationship management (CRM) technology can impact sales performance. It provides background on how assessments of past technologies have led to the acceptance of CRM systems. CRM systems help automate marketing, sales, customer support, and product configuration. The document outlines factors to consider before and after implementing a CRM system, such as costs and degree of technology usage. It also discusses potential limitations, such as over- or underutilization of the technology, and dilemmas around monitoring employee technology use. The key takeaways are that CRM, if used appropriately, can optimize task performance but descriptions of actual CRM systems and how salespeople use them are vague.
Liu Rongxuan (Article)
This document discusses the evolving definition and meaning of technology assessment (TA). It tracks how TA originated in the late 1960s focused on policy analysis and societal impacts of technology, and how the definition and practice has expanded over time. TA is now seen as integrated with technology monitoring, forecasting, and aimed at facilitating sustainable development and technology management. The document also compares TA to other forms of impact assessment such as environmental impact assessment.
Liu Rongxuan
Technology assessment involves the systematic study of the effects of technology on society. It is used by both public and private organizations to help guide decision making in a proactive or reactive manner. The process involves defining the problem, describing the technology and social context, identifying and analyzing potential impacts, evaluating policy options, and communicating results to reduce future uncertainties and help guide sustainable development.
Neo Hui Min Pearlyn
Genevieve Bell is the director of Intel's Interaction and Experience Research Group. She believes storytelling is key to understanding technology trends. TV has had the biggest impact on how we tell stories, rearranging our relationship with time, space, and others. Better technologies for creating and sharing stories will help distinguish trends from fads. While new devices and experiences will continue, people fundamentally want social engagement and a good story.
Jolene Choo
Nanorobotics involves creating machines or robots that are 10-9 meters in scale to operate inside the human body. Nanorobots called nanobots could potentially be used to kill cancer cells by producing proteins, and may enable future anti-aging and self-healing abilities by repairing damage at the cellular level. The article provides an overview of nanotechnology and its potential applications in medicine to improve health and extend human lifespans.
Dustin Yu
The document discusses an experiment where an epileptic patient was able to control video games using their mind through an implant, demonstrating a new way to control devices mentally instead of physically. The ultimate goal is to provide a way for communication and interaction between humans and machines. Further advances in this area could have both benefits for medical purposes but also be adopted by healthy individuals, changing the relationship between humans and technology.
Cheong Yin Ying
An engineer from Duke University has proposed a hybrid solar system that uses three renewable energy technologies to convert sunlight into electricity and hydrogen for individual households. The system combines solar, electrolysis, and fuel cell technologies to efficiently capture and store solar energy. While the initial installation costs are higher than fossil fuel generators, hybrid solar systems can compete with fossil fuels and help reduce dependence on natural gas plants. The system represents an environmentally friendly and innovative approach to renewable energy generation that may be worth exploring for implementation in high-rise buildings in Singapore.
Radeya Parveen
Offshore wind farms are wind farms constructed in bodies of water to generate electricity from wind power. The document discusses the opposition to and approval of the first U.S. offshore wind farm in 2010. Key points of opposition included concerns that the giant turbines would disturb spiritual sites and burial grounds on the seabed. However, offshore wind farms help fight climate change by providing a renewable energy source with high potential due to higher and more constant wind speeds offshore.
Chen Xin Ying
Scientists have made a breakthrough in HIV treatment by altering immune cells to make them resistant to HIV. They modified T cells so they no longer express the CCR5 receptor that HIV uses to enter cells, preventing HIV from infecting the altered T cells. This represents a major step towards developing a cure for HIV as it may allow patients to stop relying on antiretroviral drugs, though more research is still needed as the altered T cells do not last forever in the body.
Chayadi Karim
The document discusses a proposed technology called the Atmospheric Vortex Engine (AVE) that could generate electricity by artificially creating tornadoes. The AVE would mix hot and cold air to spin an artificial tornado, with hot air coming from existing heat sources like coal plants. It is predicted that an AVE could generate enough electricity to power a city of 500,000 people and be cheaper than other alternative energy systems. While harnessing tornadoes presents safety and stability challenges, proponents believe the technology has potential as a future renewable energy source.
Luke Phong
The document discusses the history and current state of antimatter research. Key events include the first antihydrogen production at CERN in 2002 and the ALPHA experiment's trapping of antimatter in 2011. While inefficient as an energy source currently, antimatter holds potential applications as a power source, for spacecraft propulsion, and medical purposes like PET scans and cancer treatment. The document also raises questions about continuing funding for antimatter research and how it may change the world.
Sheryl Lim
This document summarizes an article about the possibility of producing meat in laboratories as an alternative to factory farming. It discusses Winston Churchill's prediction in 1932 that animal parts could be grown separately for food. Currently, the global livestock industry accounts for 20% of greenhouse gas emissions. The document outlines the issues with factory farming in terms of animal welfare and the environment. It notes that lab-grown meat could potentially use half the energy and 2% of farmland compared to conventional meat production. However, there are still many technical difficulties to overcome before lab-grown meat becomes commercially viable.
Lenard Lee - Food Ec & Consumer Choice
1) The global population is projected to reach 9 billion by 2050, requiring a 100% increase in global food production using virtually the same amount of land as today.
2) The UN FAO states that 70% of the additional food supply must come from efficiency-enhancing agricultural technologies, as only 20% can come from additional farmland and 10% from increased cropping intensity.
3) Failure to use science-based agricultural technologies and innovations to boost food production efficiency will have disastrous consequences, as a growing global population demands more safe, nutritious, and affordable food.
Terrence Liong
The document discusses genetically modified organisms (GMOs) and their role in agriculture. It notes that while GMOs are controversial due to safety and environmental risks, they are becoming more widespread globally to meet the needs of a growing population. The use of GMO crops and land for cultivation has increased substantially in recent years. The document argues that GMOs offer benefits to consumers like enhanced nutritional qualities and are difficult to resist due to traits like pesticide and drought resistance.
Tristan Neo
The document discusses a feasibility study assessing the policy impact of green technology initiatives to promote sustainable agriculture development in selected member countries of ESCAP-APCAEM. It provides background on APACEM and green technology, examines factors for selecting technologies, presents situation analyses and case studies on biogas in Nepal and biofuels in India, and concludes with key takeaways and an assessment of how green technologies can balance environmental and business concerns.
Lenard Lee
The document summarizes the need for agricultural technology to meet increasing global food demands. By 2050, the world population is projected to reach 9 billion people with rising affluence increasing food consumption. To feed everyone, food production must increase 100% by 2050. However, only limited increases in farmland and cropping intensity are possible. Therefore, improvements and new technologies will be critical to sustainably meet future food needs in a way that keeps food affordable and gives consumers choices. Examples show how past technologies have already substantially increased production efficiencies and yields while reducing environmental impacts.
More from cynrx (20)
Recently uploaded
The Steadfast and Reliable Bull: Taurus Zodiac Sign
Explore the steadfast and reliable nature of the Taurus Zodiac Sign. Discover the personality traits, key dates, and horoscope insights that define the determined and practical Taurus, and learn how their grounded nature makes them the anchor of the zodiac.
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
Cover Story - China's Investment Leader - Dr. Alyce SU
In World Expo 2010 Shanghai – the most visited Expo in the World History
https://www.britannica.com/event/Expo-Shanghai-2010
China’s official organizer of the Expo, CCPIT (China Council for the Promotion of International Trade https://en.ccpit.org/) has chosen Dr. Alyce Su as the Cover Person with Cover Story, in the Expo’s official magazine distributed throughout the Expo, showcasing China’s New Generation of Leaders to the World.
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【网址🎉ac55.net🎉】
【网址🎉ac55.net🎉】欧洲杯赌球是世界上历史最悠久的博彩公司之一。其历史可以追溯到十九世纪末，确切时间是1886年。这家英国公司拥有超过15000名员工，是博彩行业规模最大的公司。欧洲杯赌球是英国最受欢迎的实体博彩公司之一，其排名仅次于欧洲杯赌球，旗下2800家投注站遍布全英国。
Discover the Beauty and Functionality of The Expert Remodeling Service
Unlock your kitchen's true potential with expert remodeling services from O'Brien Group Inc. Transform your space into a functional, modern, and luxurious haven with their experienced professionals. From layout reconfiguration to high-end upgrades, they deliver stunning results tailored to your style and needs. Visit obriengroupinc.com to elevate your kitchen's beauty and functionality today.
Digital Transformation Frameworks: Driving Digital Excellence
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This presentation is a curated compilation of PowerPoint diagrams and templates designed to illustrate 20 different digital transformation frameworks and models. These frameworks are based on recent industry trends and best practices, ensuring that the content remains relevant and up-to-date.
Key highlights include Microsoft's Digital Transformation Framework, which focuses on driving innovation and efficiency, and McKinsey's Ten Guiding Principles, which provide strategic insights for successful digital transformation. Additionally, Forrester's framework emphasizes enhancing customer experiences and modernizing IT infrastructure, while IDC's MaturityScape helps assess and develop organizational digital maturity. MIT's framework explores cutting-edge strategies for achieving digital success.
These materials are perfect for enhancing your business or classroom presentations, offering visual aids to supplement your insights. Please note that while comprehensive, these slides are intended as supplementary resources and may not be complete for standalone instructional purposes.
Frameworks/Models included:
Microsoft’s Digital Transformation Framework
McKinsey’s Ten Guiding Principles of Digital Transformation
Forrester’s Digital Transformation Framework
IDC’s Digital Transformation MaturityScape
MIT’s Digital Transformation Framework
Gartner’s Digital Transformation Framework
Accenture’s Digital Strategy & Enterprise Frameworks
Deloitte’s Digital Industrial Transformation Framework
Capgemini’s Digital Transformation Framework
PwC’s Digital Transformation Framework
Cisco’s Digital Transformation Framework
Cognizant’s Digital Transformation Framework
DXC Technology’s Digital Transformation Framework
The BCG Strategy Palette
McKinsey’s Digital Transformation Framework
Digital Transformation Compass
Four Levels of Digital Maturity
Design Thinking Framework
Business Model Canvas
Customer Journey Map
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
Lithium Will Power Us For The Next 50 Years And Then Robots: Kirill Klip GEM Royalty TNR Gold Lithium Presentation
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...❼❷⓿❺❻❷❽❷❼❽ Dpboss Kalyan Satta Matka Guessing Matka Result Main Bazar chart
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night IMG_20240615_091110.pdf dpboss guessing
Satta matka fixx jodi panna all market dpboss matka guessing fixx panna jodi kalyan and all market game liss cover now 420 matka office mumbai maharashtra india fixx jodi panna
Call me 9040963354
WhatsApp 9040963354
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Transport Solution
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
Prescriptive analytics BA4206 Anna University PPT
Business analysis - Prescriptive analytics Introduction to Prescriptive analytics
Prescriptive Modeling
Non Linear Optimization
Demonstrating Business Performance Improvement
Kirill Klip GEM Royalty TNR Gold Copper Presentation
Tesla Energy rEVolution And The Golden Age For Copper: Kirill Klip GEM Royalty TNR Gold Copper Presentation
Efficient PHP Development Solutions for Dynamic Web Applications
Unlock the full potential of your web projects with our expert PHP development solutions. From robust backend systems to dynamic front-end interfaces, we deliver scalable, secure, and high-performance applications tailored to your needs. Trust our skilled team to transform your ideas into reality with custom PHP programming, ensuring seamless functionality and a superior user experience.
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...
50 million companies worldwide leverage WhatsApp as a key marketing channel. You may have considered adding it to your marketing mix, or probably already driving impressive conversions with WhatsApp.
But wait. What happens when you fully integrate your WhatsApp campaigns with HubSpot?
That's exactly what we explored in this session.
We take a look at everything that you need to know in order to deploy effective WhatsApp marketing strategies, and integrate it with your buyer journey in HubSpot. From technical requirements to innovative campaign strategies, to advanced campaign reporting - we discuss all that and more, to leverage WhatsApp for maximum impact. Check out more details about the event here https://events.hubspot.com/events/details/hubspot-new-delhi-presents-unlocking-whatsapp-marketing-with-hubspot-integrating-messaging-into-your-marketing-strategy/
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
In a world where the potential of youth innovation remains vastly untouched, there emerges a guiding light in the form of Norm Goldstein, the Founder and CEO of EduNetwork Partners. His dedication to this cause has earned him recognition as a Congressional Leadership Award recipient.
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【网址🎉ac22.net🎉】
【网址🎉ac22.net🎉】欧洲杯投注是体育博彩和在线赌场之一，得益于UKGC的三项许可。 成立之初是三名博彩公司将40家博彩商店的合并的结果，共同创建一家名为欧洲杯投注的公司。 欧洲杯投注在线赌场为游戏爱好者提供了300多种游戏，其中200多种老虎机，其他游戏包括二十一点，轮盘，真人荷官和真人赌场等。
Recently uploaded (20)
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
Cover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SU
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
Digital Transformation Frameworks: Driving Digital Excellence
Digital Transformation Frameworks: Driving Digital Excellence
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
Kirill Klip GEM Royalty TNR Gold Copper Presentation
Kirill Klip GEM Royalty TNR Gold Copper Presentation
Efficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web Applications
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
Evangeline Chee
- 1. China AND INDIA MAKING INROADS IN BIOTECH DRUGS New York Times, 18 September 2011
- 2. Definitions Brand-name drug = a drug that has a trade name and is protected by a patent Patent = exclusive rights to produce and sell a product Generic drug = cheaper but equally effective version of brand-name drug; manufactured without a licence and after the patent has expired
- 3. Interesting points How developing countries attempt to circumvent patents How the pharmaceutical industry and richer nations are fighting back Similarities between the current dilemma over cancer drugs and the one over AIDS 10 years ago
- 4. Key takeaways China and India can now copy the biotech drugs used to treat cancer, diabetes and other non-communicable diseases Effect Pharmaceutical companies and richer countries vs developing countries Reduce healthcare costs
- 5. Why I chose this topic Has a legal element Reflects the need to weigh competing policy considerations Rating: 8/10
- 6. Discussion questions Who will win the battle? Will developing countries be able to get the pharmaceutical industry to give up their patent rights for cancer drugs (and the accompanying profits)? Who should win the battle?